A Novel Method to Determine HIV Incidence Among Youth
- Conditions
- HIV Infection
- Registration Number
- NCT00103883
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Brief Summary
Identifying young people with early HIV-1 infection is important for increasing linkage to care, for behavioral counseling, and for enrolling individuals into programs that can provide effective interventions to disease progression and improve outcome. This study will develop and evaluate a saliva-based sensitive/less sensitive (S/LS) assay for differentiating persons with recent HIV-1 infection (less than 133 days) from those with established HIV-1 infection.
- Detailed Description
HIV infection incidence estimates are important, not only for determining specific populations where community HIV education sessions can have the most benefit or where changes in infection patterns are occurring, but also to target these populations for therapeutic interventions and measure their effect in the community. It is estimated that half of all new HIV infections in the United States occur in persons under the age of 25 each year, translating to approximately 20,000 new HIV-infected young people annually.
Incidence can be estimated by testing a cohort of individuals for antibody at two different time periods and observing the number of new infections, or by demonstrating the presence of HIV p24 or viral RNA in antibody-negative persons. Since these strategies are logistically difficult, expensive, and/or require significant laboratory infrastructure, new laboratory-based strategies were devised that can classify individuals as recently infected or with established infection. These serologic assays are known as "sensitive/less sensitive (S/LS) assays". They are based on either the concept of antibody titer or the concept of antibody avidity. There are several S/LS tests available but all of them are performed on serum collected via venipuncture. Based on several studies showing that obtaining saliva is a more desirable method of collection for adolescents receiving HIV testing, it is anticipated that the collection of saliva and its use for determining HIV incidence by S/LS methods among adolescents would be a valuable adjunct for population studies and for increasing compliance for testing and enrollment.
The aim of this study is to prove equivalence between the serum S/LS reference method (CDC validated serum S/LS Dilutional Vironostika (DV) from Organon Teknika) and the experimental method that uses an FDA approved saliva collection device (OraSure Technologies). Our rationale follows a syllogism, i.e., if the serum S/LS EIA (DV) is the best serologic method to determine incidence estimates and a saliva S/LS method is found to perform equivalently, then it follows that the saliva S/LS method can be used effectively to determine incidence. Therefore, our purpose is to show equivalence between the two assays. To address the issue of accuracy, further studies are planned to assess the saliva S/LS test against seroconversion panels where the exact time of acquisition of HIV infection is known.
This is a cross-sectional, laboratory-based study designed to develop and evaluate a saliva-based S/LS assay for differentiating individuals with recent HIV infection (less than 133 days) from those with established HIV infection. A total of 440 subjects will be recruited in the study. A serum and two saliva samples will be obtained from every subject. The first 40 patient samples will be used to develop and calibrate the saliva-based S/LS method. The remaining patient samples will be tested using the calibrated saliva based S/LS assay and the reference serum S/LS assay and concordance between the two methods will be analyzed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 440
- Age 12 through 24 years
- HIV infection determined by routine HIV testing strategies
- Ability to give informed consent or assent with parental permission, where required
- Visibly distraught or emotionally unstable
- Intoxicated or under the influence of psychoactive agents
- First disclosure of sexual, physical, or emotional abuse
- Clinically presents as acutely ill
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I - Serum-based S/LS assay result 15-20 Months To develop and calibrate a saliva S/LS assay using the FDA licensed OraSure collection device in conjunction with its matched saliva EIA assay to differentiate persons with recent versus established HIV infection (Phase I)
Phase II - Saliva-based S/LS assay result 15-20 Months To assess that the saliva S/LS method performs equivalently to the reference serum S/LS method for HIV incidence estimates in populations of youth (Phase II)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
University Pediatric Hospital
🇵🇷San Juan, Puerto Rico
Children's Hospital of Los Angeles
🇺🇸Los Angeles, California, United States
University of California at San Diego
🇺🇸San Diego, California, United States
University of California at San Francisco
🇺🇸San Francisco, California, United States
Children's National Medical Center
🇺🇸Washington, DC, District of Columbia, United States
Children's Diagnostic and Treatment Center
🇺🇸Fort Lauderdale, Florida, United States
University of Miami
🇺🇸Miami, Florida, United States
University of South Florida
🇺🇸Tampa, Florida, United States
Stroger Hospital of Cook County
🇺🇸Chicago, Illinois, United States
University of Maryland Medical School
🇺🇸Baltimore, Maryland, United States
Tulane University
🇺🇸New Orleans, Louisiana, United States
Childrens Hospital Boston
🇺🇸Boston, Massachusetts, United States
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Mount Sinai Hospital
🇺🇸New York, New York, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States